NuCana Announces Encouraging Data for NUC-3373 in Combination with Anti-PD-1 Therapy
NuCana plc - American Depositary Shares (NCNA)
Last nucana plc - american depositary shares earnings: 3/10 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/ncna/historical
Company Research
Source: GlobeNewswire
NUC-3373 Plus Pembrolizumab Continues to Show Favorable Efficacy and Safety Profile in Heavily Pre-treated Patients Latest Data Cut-Off Shows Patient with Melanoma Remains Progression-Free at 23 Months with a Durable Partial Response Preclinical Data Corroborate Immunogenic Effects of NUC-3373 Observed in Patients EDINBURGH, United Kingdom, Oct. 14, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) announced the publication of new data on NUC-3373. The update includes results from the NuTide:303 clinical study, published on medRxiv, the preprint server for health sciences, together with complementary preclinical findings published in the peer-reviewed journal Public Library of Science ONE (PLOS ONE). NUC-3373, a potent thymidylate synthase inhibitor that induces DNA damage in cancer cells, has previously shown encouraging activity in combination with the PD-1 inhibitor pembrolizumab in the Phase 1/2b modular study, NuTide:303. In Module 1 of this stu
Show less
Read more
Impact Snapshot
Event Time:
NCNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NCNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NCNA alerts
High impacting NuCana plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
NCNA
News
- NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in ChinaGlobeNewswire
- NuCana Presents Encouraging Data on NUC-7738 in Combination with PD-1 Inhibitors using Primary Patient-Derived Organoids and Autologous Tumor-Infiltrating Lymphocytes at the ESMO Congress 2025 [Yahoo! Finance]Yahoo! Finance
- NuCana Presents Encouraging Data on NUC-7738 in Combination with PD-1 Inhibitors using Primary Patient-Derived Organoids and Autologous Tumor-Infiltrating Lymphocytes at the ESMO Congress 2025GlobeNewswire
- DNA Synthesis Inhibitors Market Gains Momentum with Growing Adoption in Oncology and Virology | DelveInsightPR Newswire
- DNA Synthesis Inhibitors Market Gains Momentum with Growing Adoption in Oncology and Virology | DelveInsightPR Newswire
NCNA
Sec Filings
- 11/5/25 - Form 6-K
- 10/20/25 - Form 6-K
- 10/14/25 - Form 6-K
- NCNA's page on the SEC website